Foghorn Therapeutics Inc (FHTX)

전일 마감가:

$5.49

열려 있는:

$5.62

하루 거래량:

9,033

시가총액:

$240.07M

수익:

$34.16M

순이익/손실:

$-98.43M

주가수익비율:

-2.0839

EPS:

-2.74

순현금흐름:

$-119.33M

1주 성능:

+13.07%

1개월 성능:

-14.90%

6개월 성능:

+70.45%

1년 성능:

-12.42%

1일 변동 폭

$5.62

$5.90

52주 변동 폭

$2.70

$9.97

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

명칭

Foghorn Therapeutics Inc

부문

Healthcare (1203)

산업

Biotechnology (688)

전화

617-586-3100

주소

100 Binney Street, Suite 610, Cambridge

직원

85

트위터

다음 수익 날짜

2024-05-08

최신 SEC 제출 서류

FHTX's Discussions on Twitter

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-03-28	개시	BofA Securities	Buy
2023-01-05	개시	BMO Capital Markets	Outperform
2021-11-22	개시	H.C. Wainwright	Buy
2020-11-17	개시	Cowen	Outperform
2020-11-17	개시	Goldman	Buy
2020-11-17	개시	Morgan Stanley	Overweight
2020-11-17	개시	Wedbush	Outperform

모두보기

Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

GlobeNewswire Inc.

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

GlobeNewswire Inc.

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?

Zacks Investment Research

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

GlobeNewswire Inc.

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know

Zacks Investment Research

Foghorn Therapeutics Inc (FHTX) 재무 분석

Foghorn Therapeutics Inc (FHTX) 매출 2024

Foghorn Therapeutics Inc (FHTX) 순이익 2024

Foghorn Therapeutics Inc (FHTX) 현금흐름 2024

Foghorn Therapeutics Inc (FHTX) 주당 순이익 2024

Foghorn Therapeutics Inc 주식 (FHTX) 내부자 거래